SCHEMBL7119334

SCHEMBL7119334

CCCc1c(OC2CCCC2)c2cc(F)ccc2[nH]c1=O

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 3/20 0.45
TSHR P16473 1/20 0.45
GHSR Q92847 1/20 0.42
RAB9A P51151 2/20 0.41
ALDH1A1 P00352 4/20 0.40
KDM4E B2RXH2 4/20 0.40
PDE9A O76083 2/20 0.40
HPGD P15428 2/20 0.40
MAPT P10636 1/20 0.40
HTT P42858 1/20 0.40
GSK3B P49841 1/20 0.39
MPO P05164 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
KEAP1 Q14145 1/20 0.38
NFE2L2 Q16236 1/20 0.38
JAK2 O60674 1/20 0.37
NPC1 O15118 1/20 0.36
PARP1 P09874 1/20 0.36
OPRM1 P35372 1/20 0.36
OPRL1 P41146 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7122490 0.87 HSD17B10 (0.62) HSD17B10TSHRRAB9AALDH1A1KDM4E
SCHEMBL7116744 0.86 SIRT1 (0.46) HSD17B10TSHRRAB9AALDH1A1KDM4E
SCHEMBL7124940 0.86 HSD17B10 (0.45) HSD17B10TSHRRAB9AALDH1A1KDM4E
SCHEMBL7122174 0.86 GHSR (0.39) HSD17B10TSHRGHSRALDH1A1KDM4E
SCHEMBL7117392 0.85 HSD17B10 (0.48) HSD17B10TSHRGHSRALDH1A1KDM4E
SCHEMBL7124010 0.85 SIRT1 (0.45) HSD17B10TSHRRAB9AALDH1A1KDM4E
SCHEMBL7116504 0.84 TSHR (0.42) HSD17B10TSHRGHSRRAB9AALDH1A1
SCHEMBL7114914 0.83 SIRT1 (0.46) HSD17B10TSHRRAB9AALDH1A1KDM4E
SCHEMBL7125625 0.83 KDM4E (0.43) HSD17B10TSHRRAB9AALDH1A1KDM4E
SCHEMBL7119105 0.83 MEN1 (0.53) HSD17B10TSHRRAB9AALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US claimed
US-20030069271-A1 Quinolone compounds for use in treating viral infections SMITHKLINE BEECHAM CORPORATION 2003-04-10 US disclosed
EP-1244629-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2002-10-02 EP disclosed
WO-2001046150-A2 QUINOLONE COMPOUNDS FOR USE IN TREATING VIRAL INFECTIONS GLAXO GROUP LIMITED (GB) 2001-06-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030069271-A1 Quinolone compounds for use in treating viral infections IRF3, MAVS, NQO2 HSD17B10 1601/4885TSHR 4728/4885GHSR 4328/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.